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 Abstract Text:   
 
Introduction: Acetyl-L-Carnitine (ALC) has been proposed to have beneficial effects in 
chronic neurodegenerative disorders caused by production of abnormal proteins, 
mitochondrial dysfunction and oxidative stress. Recently, our group demonstrated that 
pre-treatment with ALC confers effective neuroprotection against 3,4-
methylenedioximethamphetamine (MDMA)-induced neurotoxicity. These pre-clinical 
studies reinforce the beneficial potential of ALC as a neuroprotectant in 
neurodegenerative disorders. However, little is known about the molecular 
mechanisms underlying ALC action.  
Material and Methods: To study the molecular mechanisms involved in the 
neuroprotective features of ALC, we exposed PC12 cells, a cell line derived from rat 
adrenal pheochromocytoma, to methamphetamine (METH). The protective effect of 
ALC was assessed by treating cells with three concentrations of ALC (1.0; 0.1; and 
0.01 mM), 30 min prior to the addition of METH (1 and 100 µM). 24h and 72h after 
METH treatment cell viability (MTT assay) and Dopamine (DA) and Epinephrine 
release (HPLC). Since some authors suggested that ALC contribute to enhanced 
efficiency of glucose utilization, 18F-FDG uptake assay will allow to verify this issue, as 
well as to validate the results from MTT assay and HPLC. Medium was replaced by 
serum-free medium 2h before 18F-FDG addition and incubated for 20 min with fresh 
medium, containing 37 kBq of 18F-FDG/mL. Cells were washed, trypsinized and 
centrifuged. The pellet was lysed by adding NaOH 10mmol/L. Aliquots from cell lysates 
as well as supernatant were assayed for radioactivity by gamma-counting. Phase-
contrast microscopic analysis was also used. 
Discussion: Comparing to control, we observed a decrease in cell viability of 20% and 
40%, 24h after the addition of 1 and 100 µM of METH, respectively. At 72h these 
figures were more pronounced (20% and 90%). Treating the cells with ALC before 
METH did not result in a protective effect at 24h, but at 72h cell viability was increased 
for intermediary concentrations of ALC when using 1µM of METH. DA production was 
not significantly affected at 24h. Inversely, at 72h there was an increase in DA 
production. However, we observed a reduction in DA concentration when the higher 
concentrations of METH and ALC were used concomitantly. Similar results were 
obtained for Epinephrine. Microscopic analysis revealed that ALC may also reduce the 
METH-induced altered morphology of PC12 cells. 
Conclusion: As a whole, these preliminary results indicate that ALC might have a 
protective role that is dose and time-dependent. 
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